PDCD1 and esophageal squamous cell carcinoma: A phase 2 trial evaluating tislelizumab, a PD-1 inhibitor, in combination with carboplatin and Abraxane, reported MPR and pathological complete response (pCR) rates of 57.5% and 40% in patients with resectable ESCC (133).